These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28238712)

  • 21. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases.
    Victoria GS; Zurzolo C
    J Cell Biol; 2017 Sep; 216(9):2633-2644. PubMed ID: 28724527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of autophagy in prion protein-induced neurodegenerative diseases.
    Yao H; Zhao D; Khan SH; Yang L
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):494-502. PubMed ID: 23459558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroglial patterns are shared by cerebella from prion and prion-like disorder affected patients.
    Garcés M; Guijarro MI; Vargas A; Badiola JJ; Monzón M
    Mech Ageing Dev; 2019 Dec; 184():111176. PubMed ID: 31689427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prion-like transmission of pathogenic protein aggregates in genetic models of neurodegenerative disease.
    Pearce MM
    Curr Opin Genet Dev; 2017 Jun; 44():149-155. PubMed ID: 28441621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis).
    Gaggelli E; Kozlowski H; Valensin D; Valensin G
    Chem Rev; 2006 Jun; 106(6):1995-2044. PubMed ID: 16771441
    [No Abstract]   [Full Text] [Related]  

  • 26. Microglial cells in neurodegenerative disorders.
    Wojtera M; Sikorska B; Sobow T; Liberski PP
    Folia Neuropathol; 2005; 43(4):311-21. PubMed ID: 16416395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein aggregation and prionopathies.
    Renner M; Melki R
    Pathol Biol (Paris); 2014 Jun; 62(3):162-8. PubMed ID: 24698014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neurodegenerative amyloidoses: the yeast model].
    Vishnevskaia AB; Kushnirov VV; Ter-Avanesian MD
    Mol Biol (Mosk); 2007; 41(2):346-54. PubMed ID: 17514901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of Disease: astrocytes in neurodegenerative disease.
    Maragakis NJ; Rothstein JD
    Nat Clin Pract Neurol; 2006 Dec; 2(12):679-89. PubMed ID: 17117171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
    Yoshida K; Higuchi K; Ikeda S
    Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging plus X: multimodal models of neurodegenerative disease.
    Oxtoby NP; Alexander DC;
    Curr Opin Neurol; 2017 Aug; 30(4):371-379. PubMed ID: 28520598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein aggregates stimulate macropinocytosis facilitating their propagation.
    Yerbury JJ
    Prion; 2016 Mar; 10(2):119-26. PubMed ID: 26963158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Propagation of pathology through brain networks in neurodegenerative diseases: from molecules to clinical phenotypes.
    Agosta F; Weiler M; Filippi M
    CNS Neurosci Ther; 2015 Oct; 21(10):754-67. PubMed ID: 26031656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on pharmacological approaches to neurodegenerative diseases.
    Scatena R; Martorana GE; Bottoni P; Botta G; Pastore P; Giardina B
    Expert Opin Investig Drugs; 2007 Jan; 16(1):59-72. PubMed ID: 17155854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic prions and other human neurodegenerative proteinopathies.
    Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
    Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroprotective and neurotoxic signaling by the prion protein.
    Resenberger UK; Winklhofer KF; Tatzelt J
    Top Curr Chem; 2011; 305():101-19. PubMed ID: 21598098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptosis and oxidative stress in neurodegenerative diseases.
    Radi E; Formichi P; Battisti C; Federico A
    J Alzheimers Dis; 2014; 42 Suppl 3():S125-52. PubMed ID: 25056458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly.
    Walker LC; LeVine H
    Mol Neurobiol; 2000; 21(1-2):83-95. PubMed ID: 11327151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of miRNA Signatures in Neurodegenerative Prion Disease.
    Bellingham SA; Hill AF
    Methods Mol Biol; 2017; 1658():67-80. PubMed ID: 28861783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of Major Signaling Pathways in Prion Disease Progression Using Network Analysis.
    Newaz K; Sriram K; Bera D
    PLoS One; 2015; 10(12):e0144389. PubMed ID: 26646948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.